March 28, 2017
The Japan arm of AstraZeneca said on March 27 that it will reorganize into a business unit structure focusing on three core therapeutic areas of oncology, cardiovascular/metabolic diseases, and respiratory, effective April 1. The company already launched the Oncology Business...read more